Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables - Accured (2019 - 2025)

Spyre Therapeutics (SYRE) has disclosed Receivables - Accured for 7 consecutive years, with $3.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables - Accured rose 111.76% year-over-year to $3.6 million, compared with a TTM value of $3.6 million through Sep 2025, up 111.76%, and an annual FY2024 reading of $3.4 million, up 277.78% over the prior year.
  • Receivables - Accured was $3.6 million for Q3 2025 at Spyre Therapeutics, up from $3.5 million in the prior quarter.
  • Across five years, Receivables - Accured topped out at $3.6 million in Q3 2025 and bottomed at $100000.0 in Q3 2021.
  • Average Receivables - Accured over 5 years is $1.3 million, with a median of $650000.0 recorded in 2023.
  • The sharpest move saw Receivables - Accured tumbled 50.0% in 2021, then skyrocketed 1700.0% in 2024.
  • Year by year, Receivables - Accured stood at $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022, then skyrocketed by 800.0% to $900000.0 in 2023, then surged by 277.78% to $3.4 million in 2024, then grew by 5.88% to $3.6 million in 2025.
  • Business Quant data shows Receivables - Accured for SYRE at $3.6 million in Q3 2025, $3.5 million in Q2 2025, and $3.4 million in Q1 2025.